Eli Lilly has appointed David Ricks as president if its US business. Ricks has been at Lilly for 13 years, most recently as general manager of its Chinese operations.
The position became available following Lilly’s reorganisation which resulted in Enrique Conterno, the previous president of the US business, becoming leader of the diabetes business unit. Eric Baclet is succeeding Ricks as generally manager of Lilly China.
Georges Ugeux has resigned as director of Caraco Pharmaceuticals and has also stepped down from the board’s audit, compensation and independent committees. In his resignation letter Ugeux said he had disagreements with the majority shareholder and senior management.
Caraco believes that these disagreements relate to the role of the independent directors going forward in managing the US Food and Drug Administration’s (FDA) actions.
Ipsen has appointed Claude Bertrand as executive vice president (VP), chief scientific officer and member of the executive committee. Bertrand has worked in the industry for 20 years at companies including AstraZeneca, Roche Bioscience and Pfizer.
Jeff Baxter has been appointed as CEO of Variation Biotechnologies. Baxter replaces Francisco Diaz-Mitoma and was appointed in part because of his “extensive big pharma experience” at companies including GlaxoSmithKline.
AVEO Pharmaceuticals has appointed William Slichenmyer as its chief medical officer. Slichenmyer has 15 years experience in the industry at companies including Pfizer, Bristol-Myers Squibb and Merrimack Pharmaceuticals.
Jerry Treppel has been appointed as CEO of Elite Pharmaceuticals. Ashok Nigalaye has also joined the company as chief scientific officer.
CyBio has appointed Udo Werner as chief financial officer.